Our
Technology
Cell Therapy Manufacturing That Addresses Cost, Complexity, and Product Variability
Failure to reach target dose levels in immune cell therapies is often driven by suboptimal activation, affecting up to 30% of samples. Both incomplete and excessive activation contribute to manufacturing complexity, process deviations, and, in severe cases, batch failures that leave patients untreated. Emerging trends—such as accelerated manufacturing timelines, virus-free engineering, higher dosing for solid tumors, and increasingly complex CAR constructs—further intensify these challenges.
Faster, Simpler Immune Cell Manufacturing with Synecta™ Activators
Synecta cell-derived nanoparticles (CDNPs) are produced starting from a mammalian cell line. They are engineered to present defined combinations of signals, including stimulatory signals, co-stimulator ligands, membrane-bound cytokines, and others. Their natural membrane contains adhesion molecules that promote the formation of immunological synapses, driving faster and more robust activation and expansion of functional immune cells for cell therapy.
Using cell disruption and filtration technologies, Synecta™ CDNPs are engineered vesicles that mimic physiological activation and expansion conditions. Their hallmark is early and efficient T cell activation, enabling faster manufacturing cycles, consistent expansion, and immediate Day 0™ lentiviral transduction. Synecta variants with membrane-bound cytokines eliminate the need for soluble recombinant cytokine supplementation. Because the materials are biodegradable, there is no need for bead removal or residual material testing.
In short, the Synecta platform is designed to simplify and accelerate cell therapy manufacturing while reliably producing cells with the desired properties and quantities.